Biocon To Divest AxiCorp For $58M

29 April, 2011

Bangalore-based Biocon Ltd is looking to divest its majority stake in its German drug distribution subsidiary AxiCorp to the minority shareholders of the firm and take back licence rights for biosimilar insulin and glargine in Germany. Although Biocon did not say for how much it intends to sell the stake for, agency reports quoting Biocon CMD Kiran Mazumdar Shaw said that the firm is looking to pocket around €40 million or $58.7 million.

The country’s largest biotechnology firm Biocon had acquired 70 per cent in AxiCorp Gmbh for €30 million ($44 million) three years ago, to enable the marketing and distribution of a range of pharmaceuticals including generics, biosimilars, biologies and innovative pharmaceutical products in Germany and Europe. AxiCorp is a specialised marketing and distribution company established in 2002 by a group of industry experts to address the lucrative generics and parallel distribution market in Germany and Europe.

On Thursday, Biocon has said that its global alliance with world’s largest drug-maker Pfizer – struck last October – is behind the divestment decision as the synergies derived from the international deal with Pfizer can be leveraged for the German market as well. The deal with Pfizer gave the US-based drug-maker the global rights to commercialise biosimilar diabetes treatments.

Biocon will pocket around 33 per cent in gains in Euro terms but will pocket more in Rupee terms as Indian currency has depreciated against the Euro in the meantime.

AxiCorp, which contributed over a quarter of Biocon’s revenues, has been weighing on the financials of Biocon as the German government has asked for compulsory discounts from drug-makers to cut healthcare costs in the country.

Biocon scrip dropped 4 per cent to close at Rs 370 in a weak Mumbai market on Thursday.

Biocon reported 25 per cent rise in net profit for the fourth quarter ended March, 2011, that saw the total income rise by a modest 8 per cent to Rs 717 crore.


Leave Your Comment
Biocon’s arm Syngene appoints Peter Bains as CEO

Biocon’s arm Syngene appoints Peter Bains as CEO

Jasleen Kaur Batra 2 years ago
Syngene International, a subsidiary of biopharmaceutical major Biocon Ltd, has appointed Peter Bains as chief operating officer, as per a stock market disclosure. Bains has...
Biocon plans IPO for IVFA-backed drug discovery services arm Syngene

Biocon plans IPO for IVFA-backed drug discovery services arm Syngene

Jasleen Kaur Batra 3 years ago
Biocon Ltd is looking to offload up to 15 per cent in its research arm Syngene International, a firm in which mid-market private equity firm...
Pfizer to Sell Biosimilar Insulins in Biocon Deal

Pfizer to Sell Biosimilar Insulins in Biocon Deal

Reuters 7 years ago
Pfizer Inc will sell insulin made by India’s Biocon Ltd in a deal that deepens the world’s largest drugmaker’s push into biosimilar medicines and diabetes....
No Comments

Biocon To Divest AxiCorp For $58M

Powered by WordPress.com VIP